Erratum: Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama Study (Nephrology Dialysis Transplantation (2010) DOI:10.1093/ndt/gfq062);Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama study

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2557-2564

  Nagata, Masaharu ^a   Ninomiya, Toshiharu ^a   Doi, Yasufumi ^a   Yonemoto, Koji ^a   Kubo, Michiaki ^a   Hata, Jun ^a   Tsuruya, Kazuhiko ^a   Iida, Mitsuo ^a   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

chronic kidney disease; general population; hypertension; metabolic disorder; prevalence

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SEX DIFFERENCE; AGED; CHRONIC DISEASE; ETHNOLOGY; HYPERTENSION; JAPAN; KIDNEY DISEASES; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; BLOOD PRESSURE; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 77954768806     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq546     Document Type: Erratum

References (45)

1. National Kidney Foundation. K/DOQI clinical practice guidelines fo chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 2002; 39: S17-S31
2. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classifi cation of chronic kidney disease: a position statement from Kidne Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005 67: 2089-2100
3. Lysaght MJ. Maintenance dialysis population dynamics: curren trends and long-term implications. J Am Soc Nephrol 2002; 13 S37-S40
4. Culleton BF, Hemmelgarn BR. Is chronic kidney disease a cardiovascular disease risk factor? Semin Dial 2003; 16: 95-100
5. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
6. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
7. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study. J Am Soc Ne- phrol 2003; 14: 131-138
8. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
9. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-2284
10. Perkovic V, Cass A, Patel AA et al. High prevalence of chronic kidney disease in Thailand. Kidney Int 2008; 73: 473-479
11. Imai E, Horio M, Watanabe T et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-630
12. White SL, Chadban SJ, Jan S et al. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008; 86: 229-237
13. Nakai S, Masakane I, Akiba T et al. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial 2008; 12: 428-456
14. Katsuki S. Epidemiological and clinicopathological study on cerebro- vascular disease in Japan. Prog Brain Res 1966; 21: 64-89
15. Omae T, Ueda K, Kikumura T et al. Cardiovascular deaths among hypertensive subjects of middle to old age: a long-term follow-up study in a Japanese community. In: G Onesti, KE Kim (eds). Hypertension in the Young and Old. New York, NY: Grune & Stratton, 1981; 285-297
16. Fujishima M, Kiyohara Y, Kato I et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996; 45: S14-S16
17. Kubo M, Kiyohara Y, Kato I et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama Study. Stroke 2003; 34: 2349-2354
18. Doi Y, Kubo M, Yonemoto K et al. Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. J Clin Endocrinol Metab 2008; 93: 3425-3429
19. Kubo M, Hata J, Doi Y et al. Secular trends in the incidence and risk factors of ischemic stroke and its subtypes in the Japanese population. Circulation 2008; 118: 2672-2678
20. Imai E, Horio M, Nitta K et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am JKidney Dis 2007; 50: 927-937 (Pubitemid 350130278)
21. Alberti KG, Eckel RH, Grundy SM et al. Metabolic syndrome was defined by using criteria recommended in a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
22. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004; 160: 301-305
23. Chobanian AV, Bakris GL, Black HR et al. Seventh report ofthe Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
24. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290
25. Iseki K, Kohagura K, Sakima A et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res 2007; 30: 55-62
26. Yoneda M, Yamane K, Jitsuiki K et al. Prevalence of metabolic syndrome compared between native Japanese and Japanese-Americans. Diabetes Res Clin Pract 2008; 79: 518-522
27. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091
28. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850
29. Ninomiya T, Kiyohara Y, Kubo M et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006; 48: 383-391
30. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140
31. Ninomiya T, Kiyohara Y. Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr 2007; 2: 104-107
32. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-1608
33. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 2005; 142: 342-351
34. de Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892
35. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
36. Solomon SD, Rice MM, Jablonski KA et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE Inhibition (PEACE) trial. Circulation 2006; 114: 26-31
37. Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18: 2766-2772
38. Ninomiya T, Perkovic V, Gallagher M et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008; 73: 963-970
39. Ninomiya T, Kiyohara Y, Tokuda Y et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease: an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 2008; 118: 2694-2701
40. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
41. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
42. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with ne- phropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
43. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010 (Pubitemid 34286537)
44. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
45. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951